Premium
The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition
Author(s) -
Ma Elise L.,
Choi Yoon Jeong,
Choi Jinyoung,
Pothoulakis Charalabos,
Rhee Sang Hoon,
Im Eunok
Publication year - 2010
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.25011
Subject(s) - probiotic , cyclin d1 , biology , colorectal cancer , cancer research , growth inhibition , cell growth , cancer , microbiology and biotechnology , cell , cell cycle , bacteria , biochemistry , genetics
A wealth of data implicates that ErbB receptors have essential roles in tumor development. Probiotic bacteria are known to exert an anticancer activity in animal studies. Bacillus polyfermenticus (B.P.), a probiotic bacterium, has been clinically used for a variety of gastrointestinal disorders in East Asia. Here, we investigated the effect of B.P. on the growth of tumors and its putative mechanism of actions. Conditioned medium of B.P. cultures (B.P. CM) inhibited the growth of human colon cancer cells including HT‐29, DLD‐1 and Caco‐2 cells. Moreover, B.P. CM suppressed colony formation of HT‐29 cells cultured on soft agar and reduced carcinogen‐induced colony formation of normal colonocytes. Furthermore, data from the mouse xenograft model of human colon cancer cells showed reduced tumor size in B.P. CM‐injected mice when compared to E. coli conditioned medium‐injected mice. Exposure of B.P. CM to HT‐29 cells for 24 hr, 48 hr and 2 weeks reduced ErbB2 and ErbB3 protein expression as well as mRNA levels. Moreover, cyclin D1 expression that is required for ErbB‐dependent cell transformation was decreased by B.P. CM. Furthermore, transcription factor E2F‐1 that regulates cyclin D1 expression was also decreased by B.P. CM. These results show that B.P. inhibits tumor growth and its anticancer activity occurs, at least in part, through suppressing ErbB2 and ErbB3. Taken together, our study suggests that this probiotic may be clinically used as a prophylactic treatment to prevent colon cancer development.